Developer docs
API playgroundTry for free, no card

Search company profiles

SHARx

Full company profile

uuid000atw7

Namestring
SHARx
Legal namestring
SHARx LLC
Websiteurl
sharxplan.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

SHARx (SHARx LLC), founded in 2017 and headquartered in St. Louis, Missouri, is a privately held pharmacy procurement and advocacy company that helps self-funded employers and their employees access high-cost specialty medications outside traditional insurance and PBM channels. Its core product is a procurement and supply chain management solution that sources brand-name, FDA-approved medications through domestic and international supply chains (including Canada), supported by a dedicated staff of advocates and an on-staff pharmacist. SHARx also operates a proprietary member portal where members can view medication information, communicate with advocates, and track prescriptions.

The company monetizes via a flat, predictable per-employee-per-month (PEPM) fee charged to employers — a structure designed so that SHARx does not profit from higher drug costs, in contrast to spread-based PBM economics. Go-to-market is built around three reinforcing channels: a broker/benefits-consultant network (the "Rising Tides Army" — 246 brokerages and 375 brokers), direct enterprise sales to self-funded employers emphasizing fiduciary and PBM-transparency narratives, and a grassroots/community-led motion featuring WNBA, NFL, and PGA brand ambassadors. Customers include 1,025+ self-funded employers across 45 states, with cumulatively 780,000+ members served and over $1.14B in medications sourced since inception.

SHARx does not publish financials, has no disclosed funding history, and operates as a founder-led LLC (Corey Durbin, CEO; Paul Pruitt, CGO; Joe Reddy, CTO; Eric DuBois, COO). The company's growth is anchored in a mission-driven narrative tied to co-founder Paul Pruitt's personal experience with two sons requiring medications costing nearly $2.5M/year per child. Operational risks include a pending lawsuit from Genentech and Novartis over Canadian-imported Xolair shipments alleging cold-chain failures — a precedent that could materially affect the international sourcing model.

Short descriptiontext

SHARx is a private, St. Louis–based pharmacy procurement and advocacy company founded in 2017 that uses non-insurance, flat per-employee-per-month pricing to help self-funded employers and their members access high-cost specialty medications via global sourcing and dedicated clinical advocates.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSt Louis, United States
HQ citystring
St Louis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty medication procurement, pharmacy benefit management, prescription cost containment, self-funded employer benefits, global drug sourcing
Industry1 code
PRIMARYHLAIAKAF
International Reference Pricing (IRP) & External Price Benchmarking
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing
NAICS code1 code
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmacy Benefit Procurement Services
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model2 records
1Per-Employee-Per-Month (PEPM) Fees
TypeSubscription Recurring
Description

SHARx charges employers a flat, predictable per-employee-per-month fee regardless of which medications are needed. This creates alignment between SHARx and employer interests—the company is not incentivized to rely on any particular sourcing option and clients do not pay more when employees need expensive medications.

sharxplan.com
2Procurement Services for High-Cost Medications
TypeManaged Services
Description

Revenue generated through sourcing high-cost and specialty medications from domestic and international supply chains. The company uses non-insurance sourcing methods to find medications at the lowest possible prices, with the fee structure designed to keep incentives aligned.

sharxplan.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1Flat fee per employee per month with no variability based on medication costs
ModelSubscriptionBilling cadenceMonthly
Notes

Quote-based pricing determined through consultation with brokers or direct employer engagement. No disclosed price points publicly available.

sharxplan.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

SHARx is a non-insurance procurement and supply chain management solution that helps self-funded employers and their members access high-cost specialty and brand-name prescription medications at reduced prices. The company uses domestic and international sourcing, including imports from Canada, combined with a flat per-employee-per-month (PEPM) fee model and a member portal supported by clinical advocates to navigate prior authorizations, formulary exclusions, and pricing barriers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Medication costs reduced from $734 to $20 for individual members
+4 more records
Product overview1 text field

SHARx is a prescription drug procurement management solution that operates as a unified platform combining technology-enabled member services with advocacy support. The core offering consists of the SHARx Core Platform—a procurement and supply chain management solution for high-cost prescription drugs—complemented by the Member Portal (an intuitive online interface for medication management and advocate communication) and Advocate Services (compassionate clinical support). SHARx also runs the Rising Tides Army, a grassroots advocacy community, and the Rising Tides Podcast for industry education. The company uses non-insurance sourcing methods and flat-fee pricing to provide transparent, predictable access to specialty medications for employers and their employees.

Product and service3 records
1SHARx Core Platform
CategoryPharmacy Benefit Procurement
Description

A procurement and supply chain management solution for high-cost prescription drugs that helps employers navigate the complex market of specialty medications using non-insurance sourcing methods, providing flat-fee pricing and global procurement to ensure members access essential medications at the lowest possible price.

2Member Portal
CategoryMember Service Platform
Description

An intuitive online platform that allows members to manage their medications, track savings, communicate with advocates, and access prescription information through streamlined onboarding and white-glove service.

3Advocate Services
CategoryClinical Advocacy Services
Description

Dedicated team of experienced, compassionate advocates including on-staff clinical staff who provide ongoing support to members and work directly with providers to ensure members receive prescribed medications and access to care.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierSupportingTypeGTM or Marketing PartnerAnnounced on2025-12-11
Description

SHARx engaged JOTO PR Disruptors in December 2025 to promote prescription cost reform in the U.S. The campaign highlights SHARx's transparent and affordable medication model amidst rising drug costs and opaque pricing.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Rightway provides pharmacy navigation and member advocacy services that help employees access medications more affordably, overlapping with SHARx's white-glove advocacy and member portal. While not a PBM, it competes for employer budget allocation on specialty drug management.

TypeDirect peer
Description

Capital Rx operates a transparent, pass-through PBM (Judi) that eliminates spread pricing and aligns incentives with employers, very similar to SHARx's flat-fee, non-spread model. Both target self-funded employers frustrated by traditional PBM economics, making them direct competitors in the transparent PBM category.

TypeBroad incumbent
Description

Express Scripts is one of the three largest U.S. PBMs and the primary incumbent SHARx positions against in its marketing. Its legacy spread-pricing model and large employer footprint define the status quo SHARx is disrupting for self-funded plans.

TypeBroad incumbent
Description

Optum Rx is the largest U.S. PBM by script volume and part of UnitedHealth Group's integrated payer-provider-services platform. It represents the dominant incumbent in pharmacy benefit management that SHARx's transparent, flat-fee approach is designed to displace at self-funded employers.

TypeBroad incumbent
Description

MedImpact is an independent, primarily pass-through PBM that serves health plans and self-funded employers. It competes broadly with SHARx in the specialty and commercial PBM space while operating at larger scale across more benefit designs.

TypeDirect peer
Description

True Rx Management is a transparent, pass-through PBM serving self-funded employers with aligned-incentive economics closely mirroring SHARx's model. It competes directly for broker-distributed employer business and emphasizes fiduciary-grade pharmacy benefit management.

TypeDirect peer
Description

EmpiRx Health is a clinically driven PBM using a value-based, aligned-incentive model to manage specialty drug spend for self-funded employers. It serves the same customer segment as SHARx and competes on transparency and outcome-based pricing.

TypeDirect peer
Description

SmithRx is a transparent, technology-forward PBM purpose-built for self-funded employers with a flat per-member-per-month pricing model analogous to SHARx's PEPM structure. It competes head-to-head with SHARx for the same broker-distributed, self-funded employer accounts.

TypeEmerging player
Description

Cost Plus Drugs offers transparent, cost-plus pricing on a rapidly expanding formulary, attacking the same opaque US drug pricing problem SHARx addresses. While direct-to-consumer today, its expansion into employer-channel benefits creates partial overlap with SHARx's employer value proposition.

10RxBenefits
TypeDirect peer
Description

RxBenefits is a PBM optimizer and procurement partner that works through benefit brokers and consultants to help self-funded employers control prescription drug spend. Both companies operate in the broker-distributed employer pharmacy procurement space with aligned-incentive language.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SHARx

Pharmacy Benefit Procurement Servicessharxplan.com

SHARx is a private, St. Louis–based pharmacy procurement and advocacy company founded in 2017 that uses non-insurance, flat per-employee-per-month pricing to help self-funded employers and their members access high-cost specialty medications via global sourcing and dedicated clinical advocates.

What SHARx does

SHARx (SHARx LLC), founded in 2017 and headquartered in St. Louis, Missouri, is a privately held pharmacy procurement and advocacy company that helps self-funded employers and their employees access high-cost specialty medications outside traditional insurance and PBM channels. Its core product is a procurement and supply chain management solution that sources brand-name, FDA-approved medications through domestic and international supply chains (including Canada), supported by a dedicated staff of advocates and an on-staff pharmacist. SHARx also operates a proprietary member portal where members can view medication information, communicate with advocates, and track prescriptions.

The company monetizes via a flat, predictable per-employee-per-month (PEPM) fee charged to employers — a structure designed so that SHARx does not profit from higher drug costs, in contrast to spread-based PBM economics. Go-to-market is built around three reinforcing channels: a broker/benefits-consultant network (the "Rising Tides Army" — 246 brokerages and 375 brokers), direct enterprise sales to self-funded employers emphasizing fiduciary and PBM-transparency narratives, and a grassroots/community-led motion featuring WNBA, NFL, and PGA brand ambassadors. Customers include 1,025+ self-funded employers across 45 states, with cumulatively 780,000+ members served and over $1.14B in medications sourced since inception.

SHARx does not publish financials, has no disclosed funding history, and operates as a founder-led LLC (Corey Durbin, CEO; Paul Pruitt, CGO; Joe Reddy, CTO; Eric DuBois, COO). The company's growth is anchored in a mission-driven narrative tied to co-founder Paul Pruitt's personal experience with two sons requiring medications costing nearly $2.5M/year per child. Operational risks include a pending lawsuit from Genentech and Novartis over Canadian-imported Xolair shipments alleging cold-chain failures — a precedent that could materially affect the international sourcing model.

SHARx firmographics

Firmographics
Name
SHARx
Legal name
SHARx LLC
Website
https://sharxplan.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
SHARx is a private, St. Louis–based pharmacy procurement and advocacy company founded in 2017 that uses non-insurance, flat per-employee-per-month pricing to help self-funded employers and their members access high-cost specialty medications via global sourcing and dedicated clinical advocates.
Ownership category
akta.pro rank

SHARx industry classification

Industry
Product category
Pharmacy Benefit Procurement Services
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAKAF
International Reference Pricing (IRP) & External Price Benchmarking
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing

Keywords

  • Specialty medication procurement
  • Pharmacy benefit management
  • Prescription cost containment
  • Self-funded employer benefits
  • Global drug sourcing

Where SHARx is headquartered

Location

Headquarters

HQ city
St Louis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

SHARx business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Per-Employee-Per-Month (PEPM) Fees: SHARx charges employers a flat, predictable per-employee-per-month fee regardless of which medications are needed. This creates alignment between SHARx and employer interests—the company is not incentivized to rely on any particular sourcing option and clients do not pay more when employees need expensive medications.
  2. Procurement Services for High-Cost Medications: Revenue generated through sourcing high-cost and specialty medications from domestic and international supply chains. The company uses non-insurance sourcing methods to find medications at the lowest possible prices, with the fee structure designed to keep incentives aligned.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyFlat fee per employee per month with no variability based on medication costs

Go-to-market motion4 records

Distribution channels4 records

Marketing channels8 records

SHARx product offering

Product offering

Core offering

SHARx is a non-insurance procurement and supply chain management solution that helps self-funded employers and their members access high-cost specialty and brand-name prescription medications at reduced prices. The company uses domestic and international sourcing, including imports from Canada, combined with a flat per-employee-per-month (PEPM) fee model and a member portal supported by clinical advocates to navigate prior authorizations, formulary exclusions, and pricing barriers.

Product overview

SHARx is a prescription drug procurement management solution that operates as a unified platform combining technology-enabled member services with advocacy support. The core offering consists of the SHARx Core Platform—a procurement and supply chain management solution for high-cost prescription drugs—complemented by the Member Portal (an intuitive online interface for medication management and advocate communication) and Advocate Services (compassionate clinical support). SHARx also runs the Rising Tides Army, a grassroots advocacy community, and the Rising Tides Podcast for industry education. The company uses non-insurance sourcing methods and flat-fee pricing to provide transparent, predictable access to specialty medications for employers and their employees.

Differentiator

Problem solved

Functional benefit

Products and services

  • SHARx Core Platform A procurement and supply chain management solution for high-cost prescription drugs that helps employers navigate the complex market of specialty medications using non-insurance sourcing methods, providing flat-fee pricing and global procurement to ensure members access essential medications at the lowest possible price.
  • Member Portal An intuitive online platform that allows members to manage their medications, track savings, communicate with advocates, and access prescription information through streamlined onboarding and white-glove service.
  • Advocate Services Dedicated team of experienced, compassionate advocates including on-staff clinical staff who provide ongoing support to members and work directly with providers to ensure members receive prescribed medications and access to care.

Quantifiable outcome

  • Medication costs reduced from $734 to $20 for individual members
  • +4 more outcomes

Companies that use SHARx

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

SHARx technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

SHARx partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • JOTO PR DisruptorssupportingGTM or Marketing Partner · 11 December 2025SHARx engaged JOTO PR Disruptors in December 2025 to promote prescription cost reform in the U.S. The campaign highlights SHARx's transparent and affordable medication model amidst rising drug costs and opaque pricing.

Scale indicators8 records

Recent moves5 records

Expansion highlights5 records

SHARx competitors and assessment

Company assessment

Emerging players

  • Rightway: Rightway provides pharmacy navigation and member advocacy services that help employees access medications more affordably, overlapping with SHARx's white-glove advocacy and member portal. While not a PBM, it competes for employer budget allocation on specialty drug management.
  • Cost Plus Drugs (Mark Cuban Cost Plus Drug Company): Cost Plus Drugs offers transparent, cost-plus pricing on a rapidly expanding formulary, attacking the same opaque US drug pricing problem SHARx addresses. While direct-to-consumer today, its expansion into employer-channel benefits creates partial overlap with SHARx's employer value proposition.

Direct peers

  • Capital Rx: Capital Rx operates a transparent, pass-through PBM (Judi) that eliminates spread pricing and aligns incentives with employers, very similar to SHARx's flat-fee, non-spread model. Both target self-funded employers frustrated by traditional PBM economics, making them direct competitors in the transparent PBM category.
  • True Rx Management: True Rx Management is a transparent, pass-through PBM serving self-funded employers with aligned-incentive economics closely mirroring SHARx's model. It competes directly for broker-distributed employer business and emphasizes fiduciary-grade pharmacy benefit management.
  • EmpiRx Health: EmpiRx Health is a clinically driven PBM using a value-based, aligned-incentive model to manage specialty drug spend for self-funded employers. It serves the same customer segment as SHARx and competes on transparency and outcome-based pricing.
  • SmithRx: SmithRx is a transparent, technology-forward PBM purpose-built for self-funded employers with a flat per-member-per-month pricing model analogous to SHARx's PEPM structure. It competes head-to-head with SHARx for the same broker-distributed, self-funded employer accounts.
  • RxBenefits: RxBenefits is a PBM optimizer and procurement partner that works through benefit brokers and consultants to help self-funded employers control prescription drug spend. Both companies operate in the broker-distributed employer pharmacy procurement space with aligned-incentive language.

Broad incumbents

  • Express Scripts (Evernorth): Express Scripts is one of the three largest U.S. PBMs and the primary incumbent SHARx positions against in its marketing. Its legacy spread-pricing model and large employer footprint define the status quo SHARx is disrupting for self-funded plans.
  • Optum Rx (UnitedHealth Group): Optum Rx is the largest U.S. PBM by script volume and part of UnitedHealth Group's integrated payer-provider-services platform. It represents the dominant incumbent in pharmacy benefit management that SHARx's transparent, flat-fee approach is designed to displace at self-funded employers.
  • MedImpact Healthcare Systems: MedImpact is an independent, primarily pass-through PBM that serves health plans and self-funded employers. It competes broadly with SHARx in the specialty and commercial PBM space while operating at larger scale across more benefit designs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

SHARx social profiles

Digital presence

SHARx compliance and trust

Trust signal

Compliance1 record

SHARx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SHARx leadership team

Management profile

Number of profiles

Profiles4 records

SHARx funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SHARx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SHARx

What does SHARx do?

SHARx is a non-insurance procurement and supply chain management solution that helps self-funded employers and their members access high-cost specialty and brand-name prescription medications at reduced prices. The company uses domestic and international sourcing, including imports from Canada, combined with a flat per-employee-per-month (PEPM) fee model and a member portal supported by clinical advocates to navigate prior authorizations, formulary exclusions, and pricing barriers.

Is SHARx a public or private company?

SHARx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was SHARx founded?

SHARx was founded in 2017. It employs 51 to 100 people.

Where is SHARx based?

SHARx is headquartered in St Louis, United States, in the North America region.

How does SHARx make money?

Two revenue lines are on record. Per-Employee-Per-Month (PEPM) Fees are the primary driver. The others are procurement Services for High-Cost Medications.

Who are SHARx's main competitors?

Emerging players on record are Rightway and Cost Plus Drugs (Mark Cuban Cost Plus Drug Company). Direct peers are Capital Rx, True Rx Management, EmpiRx Health, SmithRx and RxBenefits. Broad incumbents are Express Scripts (Evernorth), Optum Rx (UnitedHealth Group) and MedImpact Healthcare Systems.

Does SHARx have an API?

No public API is recorded for SHARx.

What industry is SHARx in?

SHARx's product category is Pharmacy Benefit Procurement Services. Its primary akta.pro industry code is HLAIAKAF, International Reference Pricing (IRP) & External Price Benchmarking. Its NAICS code is 42421 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireOne Prescription Can Rewrite the Benefits Budget, SHARx WarnsSHARx warns employers that new high-cost specialty drugs can rewrite benefits budgets, citing Sun Life data showing claims over $1 million rose 46% from 2022 to 2026, with the most expensive treatment averaging $3.6 million. The company urges pre-treatment budget planning and reviewing pharmacy and medical data together.PR NewswirePatent Expiration Does Not Signal a Savings Date, Cautions SHARx's Paul PruittSHARx's Paul Pruitt warned that patent expiration does not guarantee lower drug costs, as biosimilars can take years to enter the market. He cited adalimumab, where the first biosimilar took six and a half years to launch in the U.S. He urged employers to review pharmacy benefit strategies and net costs.PR NewswireSHARx is Raising Up an Influential Rx ArmySHARx launched the Rising Tides program, bringing athletes and leaders to advocate for prescription affordability. The initiative aims to move people from awareness to action, with ambassadors like Sophie Cunningham and Brock Osweiler. SHARx expects the ambassador community to expand beyond sports.PR NewswireThe Pharmacy Budget Trap: SHARx Warns Discounts Alone Cannot Control Total SpendingSHARx warns employers that discounts alone cannot control total pharmacy spending, as rising utilization of high-cost drugs like GLP-1s can increase costs despite lower unit prices. A hypothetical example shows a 10% discount with 40% volume growth raises spending by 26%. The company urges forecasting and total-spend discipline over savings percentages.PR NewswireAs Customs Requirements Change, SHARx Focuses on Rx Continuity for Employers and PatientsSHARx is preparing employers and patients for potential disruptions to low-cost prescription drug access caused by Executive Order 14411 and a new CBP rule on October 22. The company has tested alternative entry processes and developed domestic sourcing options to maintain access. It emphasizes that the order does not ban personally imported prescription drugs but could affect medication pathways.PR NewswireSHARx Urges HR and CFO Leaders to Rethink the True Cost of Pharmacy BenefitsSHARx urges HR and CFO leaders to treat pharmacy benefits as a workforce and business issue, not just procurement. The company cites a 6% year-over-year increase in private sector health benefit costs versus 3.1% for wages, warning that cost shifting to employees does not solve the problem. It recommends joint review of pharmacy spend and forecasting to balance affordability, access, and predictability.PR NewswireSHARx Warns PBM Rebate Reform May Move Money Without Lowering Employer CostsSHARx warns that PBM rebate reform may shift revenue without lowering employer costs, citing FTC and DOL data. The FTC found affiliated pharmacies generated over $7.3 billion in dispensing revenue above costs from 2017-2022. SHARx urges employers to examine total pharmacy economics beyond contract transparency.PR NewswireMore to "The Point:" SHARx and Sophie Cunningham Turn a Viral Spotlight on Prescription AffordabilitySHARx appointed WNBA guard Sophie Cunningham as a national brand ambassador for its Rising Tides Army, using her viral spotlight to highlight prescription drug affordability. The company's pharmacy advocacy model aims to reduce costs for self-insured employers and their members.PR NewswireSHARx Says PBM Reform Should Be Measured by Results, Not HeadlinesStates across the U.S. are intensifying oversight of pharmacy benefit managers through legislative and investigative measures, including the federal Consolidated Appropriations Act of 2026 requiring full rebate pass-throughs and state actions in Arkansas and Florida. SHARx, a prescription drug procurement solution, argues that reform success should be measured by whether it lowers employer costs, improves patient access, and gives employers more control rather than by the volume of legislative activity. The company is calling for an employer scorecard approach to evaluate whether reforms produce tangible outcomes rather than just regulatory changes.PR NewswireSHARx Says Pharmacy Benefits Have Become a Major Spend Category With No Clear OwnerSHARx, a procurement management solution for high-cost prescription drugs, is calling attention to what it calls an 'accountability gap' in employer pharmacy benefits management, where one of the largest healthcare expenses lacks clear ownership among HR, finance, brokers, consultants, and PBMs. Large employers project healthcare costs will rise 9% in 2026 while pharmacy continues to grow as a larger cost burden, with the top three PBMs controlling approximately 80% of the roughly 6.6 billion prescriptions dispensed in the U.S. in 2023. SHARx argues that employers must treat pharmacy benefits as a strategic spend category with defined ownership and measurable performance expectations to address the structural fragmentation driving rising costs.